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Abstract: Recent studies revealed that micro RNA-10b (mir-10b) is highly expressed in metastatic breast cancer cells and positively 
regulates breast cancer cell migration and invasion through inhibition of HOXD10 target synthesis. In this study we designed anti-mir-10b 
molecules and combined them with poly L-lysine (PLL) to test the delivery effectiveness. An RNA molecule sequence exactly matching 
the mature mir-10b minor antisense showed strong inhibition when mixed with PLL in a wound-healing assay with human breast cell 
line MDA-MB-231. The resulting PLL-RNA nanoparticles delivered the anti-microRNA molecules into cytoplasm of breast cancer 
cells in a concentration-dependent manner that displayed sustainable effectiveness.
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Introduction
The  most  important  goal  in  treating  breast  cancer 
patients  is  to  stop  metastasis  at  the  source;  for 
  example,  by  surgery  to  eradicate  all  cancer  cells 
before they metastasize to distant organs. However, it 
has been widely reported that metastasis occurs even 
after  surgery.  Metastasis  is  a  complex,  multi-step 
process by which primary tumor cells invade adjacent 
tissue,  enter  the  systemic  circulation  (intravasate), 
translocate through the vasculature, arrest in distant 
capillaries,  extravasate  into  the  surrounding  tissue 
(parenchyma), and finally proliferate from microscopic 
growths (micrometastases) into macroscopic secondary 
tumors.1–3
Recently, it has become evident that, in addition to 
alterations in protein-encoding genes,   abnormalities 
in non-coding genes can also contribute to cancer 
  pathogenesis. In particular, a class of small   cellular 
RNAs,  termed  microRNAs  (miRNAs),  acting  as 
agents of the RNA interference pathway, can lead 
to silencing of their cognate target genes, doing so 
either by cleaving mRNA molecules or by inhibiting 
their translation.4,5 A recent screening of miRNAs 
toward inhibition of breast cancer metastasis using 
in vitro   cultivated cells and animal models ended up 
with   several anti-miRNA reagents.4,6,7 For example 
miRNA-10b (mir-10b), located on Hox gene   clusters 
was identified for its role in   positively regulating 
breast  cancer  cell    migration  and  invasion  by  the 
transcription factor Twist.6 HOXD10 was reported 
to be a direct and functional target of mir-10b.4,6,8 
RNA molecules of anti-mir-10b reduce the invasive 
properties of MDA-MB-231 breast cancer cells by 
ten fold.6 These studies established that anti-mir-10b 
RNA can be used directly to inhibit breast cancer 
metastasis. However, those foreign RNA molecules 
cannot be directly taken up by cells; several trans-
fection techniques are applied to ensure successful 
uptake of these anti-mir RNA reagents into cultured 
cells  or  animal  tissues.1,3,9  For  example,  cationic 
liposomes  are  widely  used  for  DNA  vectors  and 
RNAi  delivery,  but  with  low  efficiency  of  trans-
fections.10  Alternatively,  synthetic  polymers  and 
nanoparticles have been applied in gene delivery in 
recent years because of their potential advantages of 
low immunogenicity.11,12 Poly (L-Lysine) (PLL) has 
been widely used as a gene delivery carrier because 
of its excellent nuclei acid condensation property 
and  efficient  protection  of  nuclei  acid  from  the 
attack of nucleases.11,13–15 In this study, we used PLL 
(MW 40,000) to deliver anti-mir-RNA-10b mole-
cules into the breast cancer cell line MDA-MB231. We 
found that unmodified RNA molecules have strong 
interactions with PLL, and the formed nanoparticles 
can deliver the RNA into breast cancer cytoplasm in 
a concentration-dependent manner with sustainable 
effectiveness.
Materials and Methods
Chemical and reagents
Custom  ordered  FITC  labeled  poly  L-lysine  of 
molecular  weight  40k  Da  was  purchased  from 
Fisher  Scientific  Inc.  3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyl  tetrazolium  bromide  (MTT)  was 
purchased  from  Invitrogen  (catalog  number 
V13154).  Anti-mir-10b  RNA  major  (sequence: 
5′-CACAAAUUCGGUU-CUACAGGGUA-3′) 
and  anti-mir-10b  RNA  minor  (sequence: 
5′-ACAGAUUCGAUU-CUAGGGGAAU-3′)  were 
ordered  from  IDT  (Coralville,  IA).  Negative  RNA 
control (catalog AM4611) was ordered from Applied 
Biosystems (Austin, TX). The RNA cy5 labeling kit 
(catalog number MIR 3700) was ordered from Mirus 
Bio LLC (Madison, WI). Breast cancer cell MDA-
MB-231 was purchased from ATCC (catalog number 
HTB-26). DMEM medium and FBS were purchased 
from ATCC (catalog 30-2008). Antibody for RHOC 
was  purchased  from  Santa  Cruz  Biotechnology 
(catalog  sc-26480).  Antibody  for  beta-Actin  was 
purchased from Abcam (catalog ab8229).
Cy5 labeling of RnA
Following the kit instructions, 1 mM RNA (  including 
major  anti-micro-10b,  minor  anti-micro-10b,  and 
negative RNA) was mixed with 2 mM Cy5 label-
ing  reagent  and  incubated  at  room  temperature 
(21 °C ± 1 °C) for 2 hours. The labeled RNA mole-
cules were purified by standard procedures following 
instructions from the kit. The Cy5-labeled RNA mol-
ecules were aliquoted as 10 µM and stored at −80 °C 
before experiments.
Preparation and characterization  
of PLL-RnA nanoparticles
Anti-mir-10b  RNA  molecules  and  PLL  were  both 
dissolved  into  pure  RNAse,  DNAse-free  water 
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(Fisher Scientific, catalog number BP2484-100) and 
auto-claved at 121 °C for 30 min before experiments. 
Multiple  tubes  containing  0.5  mL  of  various 
concentration of FITC labeled PLL (2 µM to 2 mM) 
were added with a 0.5 mL of constant anti-mir-10b 
RNA  (0.5  mM)  solution,  then  vortexed  for  5  min 
and incubated for 1 hour at room temperature. For 
the fluorescence measurement, excitation wavelength 
was at 485 nm, emission wavelength at 516 nm, slit 
widths at 5 nm, accumulation time of 0.4 sec. Multiple 
tubes  containing  0.5  mL  various  concentrations 
(2 µM to 2 mM) of Cy5-labeled anti-mir-10b RNA 
was added with 0.5 mL fixed concentration of PLL 
(0.5 mM), then vortexed for 5 minutes and incubated 
for 1 hour at room temperature. The fluorescence was 
measured with a Fluoro Max-2 fluoresce photometer 
with the excitation at 630 nm, emission wavelength 
at 660 nm, slit widths at 5 nm, accumulation time of 
0.4 sec.
Based on the titration of PLL to anti-mir-10b above, 
the 1:1 molar ratio was used to produce PLL-anti- 
mir-10b  nanoparticles.  2  mM  of  anti-mir-10b  was 
mixed  with  an  equal  volume  of  2  mM  PLL,  and 
  vortexed at room temperature for 5 min. The RNA 
loading  were  estimated  by  measuring  the  solution 
absorbance  at  260  nm.  During  the  reaction,  RNA 
molecules  bound  to  PLL  and  formed  micelle,  no 
detectable free RNA in the solution can be found by 
the solution absorbance at 260 nm. The final RNA 
concentration of stock of RNA-PLL was estimated 
as 1 mM. The particle size of anti-mir-10b-PLL was 
analyzed by dynamic light scattering (DLS).
DLS measurements  
of the nanoparticle size
The dynamic light scattering (DLS) instrument was 
home-built. A 532 nm laser was focused into a s  ample 
cell and the scattering light was collected by an opti-
cal  fiber. A  D532/10X  filter  (Chroma    Technology, 
  Brattleboro, VT) was used to exclude possible auto-
  fluorescence. To minimize the effect of after pulse, 
the scattering light output from the   optical fiber was 
split by a cube beam splitter (  Thorlabs, Newton, NJ), 
and detected by a pair of SPCM-AQR-14   avalanche 
  photodiodes  (Perkin-Elmer  Optoelectronics, 
Vaudreuil,  Canada).  The  output  was  fed  into  a 
Flex01-05D  multi-tau  correlator  (Correlator.com, 
Bridgewater, NJ), and the correlation   function was 
calculated in real time. An NIST traceable particle 
size  standard  (Catalog  64010,  Polysciences  Inc. 
  Warrington PA) was used to calibrate the setup.
Wound-healing assay
MDA-MB-231 cells were counted and plated 1 × 
105/well  in  24-well  tissue  culture  plates  to  achieve 
90% confluence. A vertical or   horizontal wound was 
created using a 1000-µL pipette tip. The wounded 
cells were washed three times with PBS and DMEM 
medium  with  10%  FBS,  and    covered  with  either 
anti-mir-10b contained medium or   control medium. 
The cells were then placed onto a Nikon Eclipse 
TE300 inverted microscope equipped with an envi-
ronmental chamber (In Vivo Scientific, LLC) main-
tained at 37 °C for imaging. Random fields in each 
well were selected for imaging with a Nikon Plan 
Apo 4X/0.2 objective using a Retiga 1300 cooled 
CCD  camera  (QImaging)  controlled  by    Volocity 
Acquisition  (Perkin  Elmer)  software.  The  loca-
tion of the imaged cells were recorded and saved 
with the Volocity software (Velocity Software, Inc.) 
allowing the same location to be imaged at 0 and 
24 hours. Images were captured at designated times 
to assess wound closure. The inhibition effective-
ness was   estimated by the relative distance of wound 
closure.
Confocal microscope
To obtain 3-dimensional images of the cell uptake 
of  RNA-nanoparticles,  we  used  a  Zeiss  710  laser 
scanning confocal microscope. A 20X NA 1.0 water-
dipping objective was used. The FITC and Cy5 fluoro-
phores were excited by the 488-nm and 633-nm lasers 
simultaneously. The emission band of 493–628 nm 
for the FITC-labeled PLL channel and 638–759 nm 
band for the Cy5-labeled RNA channel were recorded 
simultaneously.
in vitro toxicity assay
MDA-MB-231 cells were plated in a 96-well plate 
at a seeding density of 1×106 cells per well in 0.1 mL 
of growth medium consisting of DMEM plus 10% 
FBS. Cells were grown at 37 °C for 24 hours, and 
the  medium  was  removed.  Medium  containing 
designed PLL-anti-mir-10b nanoparticles was incu-
bated for an additional 24 hours, 100 µL of fresh 
medium containing 50 µg of MTT was added to 
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each  well,  and  cells  were  incubated  for  4  hours. 
Lysis buffer (10 (W/v) SDS, 45% DMF, pH 4.7) was 
then added and   incubated for 24 hours. Absorbance 
was    measured  at  570  nm  in  a  microplate  reader 
(Molecular  Devices  Corp.).    Survival  percentage 
was calculated as   compared to no-treatment cells 
(100% survival).
Western blot
Cells were harvested in RIPA lysis buffer (150 mM 
NaCl,  10  mM  Tris-HCl,  pH  7.5,  1%  NP40, 
1%  deoxycholate,  0.1%  SDS,  protease  inhibitor 
  cocktail (Roche)). Proteins from total cell lysate were 
analyzed by NuPAGE 4%–12% Bis-Tris   gradient gel 
(Invitrogen),  transferred  to  the  PVDF  membrane, 
blocked  with  2%  non-fat  milk  in  PBS/Tween-20, 
blotted with the antibodies for RhoC 1:200 and beta-
actin (1:10,000), and developed with anti-mouse IgG-
HRP 1:10,000 using the ECL kit from Invitrogen.
Statistics method
All wound healing experiments were repeated at least 
three  times.  The  representative  experiments  were 
reported in the figures. For the Western blot, three 
repeated experiments were carried out. The ratio of 
intensity of the RhoC bands to the actin bands were 
quantified  using  the  software  of    LumiAnalyst  3.1 
(Roche). The significant difference of anti-mir-10b 
compared  to  controls  was  based  on  the  t-test 
P value , 0.05 (n = 3).
Results
Design of anti-mir-10b RnA
Theoretically  RNA  molecule  that  can  comple-
mentarily  form  a  complex  with  mature    mir-10b 
will deplete the mir-10b, thus abolishing the mir-
10b-mediated  breast  cancer  cell  migration  and 
metastasis  (Fig.  1).  According  to  the  miRbase 
(http://www.miRbase.org), RNA sequence exactly 
complementary to mature hsa-mir-10b (major) is 
5′-CACAAAUUCGGUUCUACAGGGUA-3′. 
The  RNA  sequence  exactly  complementary  to 
mature  hsa-mir-10b*  (minor)  is  5′-ACAGAU   
UCGAUUCUAGGGGAAU-3′. Based on the pre-
dicted   secondary structure, the minor anti-mir-10b 
is more stable than major anti-mir-10b (Table S1). 
In our cell-based assays we decided to focus on the 
minor anti-mir-10b RNA molecule.
In breast cancer cytoplasm
Adding anti-mir-10b
HOXD10 HOXD10
HOXD10 HOXD10
HOXD10 ↓ HOXD10 ↑
HOXD10 target: RHOC ↑ HOXD10 target: RHOC ↓
Breast cancer
cell migration,
invasion,
metastasis
Breast cancer
cell migration,
invasion,
metastasis
AAAA
AAAA
AAAA
AAAA
mir-10b mir-10b
RISC
Figure  1.  experiment  design  of  using  anti-mir-10b  RnA  molecule  to 
inhibit  breast  cancer  metastasis.  Left  panel:  mir-10b  in  cytoplasm  of 
breast cancer is overexpressed by Twist- induced mechanism.6,8,22 This 
leads to suppression of hOXD10, which the mir-10b binds to its UTR 
region and upregulates the hOXD10 target (ie, RhOC), thus resulting 
in breast cancer cell migration, invasion, and metastasis. Right panel: 
By  adding  anti-mir-10b  RnA  mediated  by  PLL  nanoparticles,  RiSC 
(RnA induced Silence Complex) is interrupted, and the hOXD10 target 
RhoC is downregulated, thus inhibiting the breast cancer cell migration, 
  invasion, or metastasis.
nanoparticle of PLL-anti-mir-10b
The polylysine main chain served the hydrophobic 
core, and the cationic side chain of lysine served as 
a hydrophilic surface corona that interacts with nega-
tively charged RNA molecules. As we observed in our 
fluorescence titration, the fluorescence of PLL was 
quenched when PLL-anti-mir-10b formed complex. 
When the molar ratio of PLL: anti-mir-10b reached 
0.9–1, the PLL fluorescence started linearly increased 
along with the amount of PLL increased (Fig. 2A). 
The Cy5 labeled anti-mir-10b and unlabeled anti-mir-
10b showed same profile indicated the Cy5 labeling 
does not affect the binding of anti-mir-10b to PLL. 
When the PLL was titrated with different amount of 
fluorescence of Cy5 labeled anti-mir-10b, the fluores-
cence of Cy5 was measured. When the molar ratio 
of PLL : ant-mir-10b reached 0.9–1.0, the Cy5 fluo-
rescence was completely quenched (Fig. 2B). These 
two  titration  experiments  together  suggested  when 
molar ratio of PLL: anti-mir-10b was 0.9–1, the anti-
mir-10b RNA formed complex with PLL. The DLS 
further suggested that 94% population of the solution 
formed nanoparticle micelle was ∼200 nm (Fig. S1). 
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This size was reported to be ideal to deliver the RNA 
molecule to transport through cell membrane.
Cytotoxicity of PLL-micro-RnA
To identify an effective concentration of PLL-micro-
RNA without inducing cell apoptosis, the cytotoxic-
ity of these nanoparticles bearing anti-mir-10b RNA 
molecules toward MDA-MB-231 cells was examined 
using MTT assay (Fig. S2). There is essentially no 
cytotoxicity under the conditions tested (2–182 nM) 
according to MTT assay. In all of our experiments, 
50 nM of anti-mir-10b was delivered by PLL-micro-
RNA nanoparticles, and we did not observe either cyto-
toxicity or any abnormal cell morphology changes.
inhibition of breast cancer invasion  
by wound-healing assay
The  wound-healing  assay  is  widely  used  to  pres-
ent  useful  information  for  cell  proliferations  and 
cell  migration. As  previously  reported,  for  MDA-
MB-231, the cell invasion has a great correspond-
ing relationship with cell migration assay and wound 
healing. The invasion properties of cancer cells were 
measured by the wound closure in these assays. In our 
study MDA-MB-231 cells were treated with different 
concentrations of anti-mir-10b combined with PLL, 
and the wound closure was analyzed. In the   presence 
of no treatment or treatment with negative RNA mol-
ecules, the MDA-MB-231 cell can migrate into the 
scratched space in ∼24 hours (Fig. 3). With PLL-  anti-
mir-10b-treatment,  the  wound  was  still  open  after 
24 hours   indicating that anti-mir-10b delivered by PLL 
  interacted with mature mir-10b inhibiting the breast 
cancer cell migration or invasion. To further confirm 
the inhibition effectiveness, we loaded the cells with 
  different  concentrations  of  PLL-anti-mir-10b.  The 
distance  of  the  wound  closure  strongly  correlates 
with  concentration  of  PLL-anti-mir-10b  (Fig.  4). 
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Figure 2. Characterization the complex of PLL-anti-mir-10b. (A) Constant anti-mir-10b RNA (Cy5 labeled (◊), unlabeled (□)) were titrated with FITC-
labeled PLL. (B) Constant PLL was titrated with Cy5-labeled anti-mir-10b RnA.
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Figure 3. PLL-mediated anti-mir-10b inhibits breast cancer cell migration in wound-healing assay. 50 nM PLL alone (A), 50 nM anti-mir-10b (B), 50 nM 
negative control RnA molecules mixed with PLL (c), and 50 nM PLL-anti-mir-10b complex (D) were added into 1 × 105/well MDA-MB-231 cells for the 
wound-healing assay. The vertical lines indicate the wound formed at 0 hours (top panel) and 24 hours (bottom panel). Only in the D panel the wound 
healing is inhibited.
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That is the higher concentration of anti-mir-10b were 
delivered into the cell by PLL, the less chance of the 
cancer cells healed the wound.
Breast cancer cell uptake  
of anti-mir-10b RnA into cytoplasm
MicroRNAs are post-transcriptional regulators that 
bind to  complementary  sequences  of target mes-
senger RNA transcripts (mRNAs). The pre-miRNA 
hairpins are exported from the nucleus in a pro-
cess  involving  the  nucleocytoplasmic  shuttle.  In 
the cytoplasm, the pre-miRNA hairpin is cleaved 
by the Dicer. The miRNA maturation and regula-
tion of target mRNA is mainly in the cytoplasm. 
To test if the anti-mir-10b molecules are delivered 
by  nanoparticles  into  the  cytoplasma,  the  uptake 
of PLL-anti-mir-10b nanoparticles was visualized 
by  confocal  microscope.  In  our  experiments,  the 
PLL was labeled by FITC, and anti-mir-10b mol-
ecule was labeled by Cy5. As shown in Figure 5, 
both  FITC-labeled  PLL  and  Cy5-labeled  RNA 
were identified on the confocal microscope in same 
view  in  cytoplasm  of  MDA-MB-231  breast  can-
cer cells. This strongly suggested that anti-mir-10b 
RNA molecules were delivered into cytoplasm by 
PLL-anti-mir-10b nanoparticles.
Sustained release of RnA  
by nanoparticles
PLL is a very stable drug delivery reagent, and has   
been proved to tolerate with extracellular and intracellu-
lar protease. But it is still a polypeptide material, it will 
be eventually degraded by the intracellular protease in 
several weeks. In our experiments, the denatured single 
chain RNA molecule was bound to poly-lysine nano-
particles. Therefore the releasing of anti-mir-10b must 
depend on how PLL is degraded. After the first 48-hour 
experiment, we detached the MDA-MB-231 cells and 
restarted the same experiments by making a perpen-
dicular wound. In the second 48-hour experiment, the 
wound closure again showed concentration dependence 
as shown in Figure 4. We continued our assay for 4 
weeks, continuously observing the sustained inhibition 
of cancer cell migration by this wound-healing assay. 
This observation suggested that PLL-anti-mir-10b par-
ticles may slowly release the small amount of RNA to 
inhibit the mature miR-10b that was overexpressed in 
breast cancer cells.
A
B
C
D
0.2 nM 1 nM 2 nM 10 nM 20 nM 50 nM
Figure 4. PLL mediated anti-mir-10b inhibits breast cancer cell migration follows concentration-dependent manner and sustained effectiveness for 4 weeks. 
Different  passages  of  MDA-MB-231  cells  were  carried  on  the  wound-healing  assay  by  adding  different  concentration  (from  0.2  nM  to  50  nM)  of 
PLL-anti-mir-10b complex. (A) The first passage of MDA-MB-231 cells in the first week. The horizontal lines indicate the wound formed at 24 hours.   
(B) The second passage of MDA-MB-231 in the second week. The vertical lines indicate the wound formed at 24 hours. (c) The third passage of MDA-
MB-231 in the third week. The horizontal lines indicate the wound formed at 24 hours. (D) The fourth passage of MDA-MB-231 in the fourth week. The 
vertical lines indicate the wound formed at 24 hours.
14  Breast Cancer: Basic and Clinical Research 2012:6Breast cancer treatment by poly-lysine delivered anti-mir-10b
Downregulation of RhoC  
by PLL-anti-mir-10b
To confirm that  the delivered  RNA molecules can 
interfere with the regulation of miR-10b in MDA-
MD-231,  we  analyzed  the  downstream  target  of 
miR-10b by Western blot experiments. In the absence 
of PLL or anti-mir-10b, the cancer cells expressed 
RhoC at basal level (Fig. 6). When anti-mir-10b RNA 
(50 nM) was added without PLL, it did not change the 
RhoC level. When PLL (50 nM) was present along 
with anti-mir-10b molecules (50 nM), the RhoC was 
dramatically reduced (Fig. 6). When we increased the 
concentration of anti-miR-10b (100 nM), the RhoC 
was further suppressed (Fig. 6).
Discussions
To  deliver  the  anti-miR-10b  RNA  molecule  into 
breast cancer cells to inhibit the cancer metastasis, we 
developed a novel RNA-PLL complex. The nanopar-
ticles size was about 200 nm. This size was reported 
to be ideal to deliver the RNA molecule to transport 
through cell membrane.16 The wound-healing assay is 
widely used to present useful information for cell pro-
liferations and cell migrations.6,17,18 So we tested this 
nanoparticles in the wound healing assays of breast 
cancer  MDA-MB-231.  This  nanoparticle  complex 
proved highly effective because of the slow release 
of trace amount of anti-mir-10b for up to 4 weeks in 
our cell assays with no toxicity. Our data has shown 
Z = 3 µm
BF FITC Cy5 FITC-Cy5
Z = 7 µm
Z = 11 µm
Z = 15 µm
Figure 5. PLL-mediated anti-mir-10b RnA cytoplasm delivery visualized by the confocal microscope. 50 nM PLL-anti-mir-10b complex were added into 
MDA-MB-231 cells. After 28 hours, the cell monolayers were washed with 1XPBS three times. images were taken by Zeiss 710 laser scanning confocal 
microscope. FiTC-labeled PLL (green), Cy5-labeled anti-mir-10b (red), and FiTC-Cy5 merged view were visualized at 3 µm, 7 µm, 11 µm, and 15 µm 
Z-dimensions.
Anti-mir-10b
PLL
++
+
*
−
−
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−
+
+
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Actin
Figure 6. RhoC is suppressed by PLL-delivered cytoplasm anti-mir-10b 
RnA molecules. Western blot analysis of RhoC level with anti-mir-10b 
delivered  by  PLL.  With  presenting  of  50  nM  anti-mir-10b  along  with 
the constant PLL, the level of RhoC was significantly (P , 0.05, n = 3) 
decreased compared to its basal expression without adding PLL and/
or anti-mir-10b (denoted with star). When 100 nM of anti-mir-10b added 
(++), the RhoC was further suppressed (denoted with star).
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that a single dose of PLL-anti-mir-10b (50 nM) was 
sustained  in  the  cells  after  multiple  passages  and 
thus has retained the anti-metastasis function up to 
4 weeks. Although we are targeting miR-10b in this 
study, this platform could potentially be used with 
any other anti-miRNA.
As we observed in this study, microRNA molecule 
(anti-mir-10b) was bound and protected by PLL, and 
PLL-anti-mir-10b nanoparticle was capable to deliver 
microRNA  molecule  into  breast  cancer  cytoplasm 
effectively. The molecular mechanism of PLL deliv-
ery is due to the strong interactions between the RNA 
backbone  and  the  cationic  polylysine. The  formed 
nanoparticles  protected  the  microRNA  intact  from 
extracellular or intracellular nucleases. In the cyto-
plasm of human cancer cells, the pre-miRNA hair-
pin is cleaved by the Dicer. This endoribonuclease 
interacts  with  the  3′  end  of  the  hairpin  and  cuts 
away the loop joining the 3′ and 5′ arms, yielding an 
imperfect miRNA: miRNA duplex. Since the PLL 
nanoparticle was tightly bound to the anti-miR-10b, 
and  protected  it  from  RNAse  degradation,  it  may 
need more energetic efforts to release those anti-miR-
10b molecules into cytoplasm. This makes the selec-
tivity of PLL-RNA with perfectly matched mature 
mir-10b in the cytoplasm. Regardless of the 4-week 
sustainable effectiveness, the slow degradation of PLL 
in the cell may be a possible mechanism as reported 
previously.19–21 Considering the cell proliferation, the 
initial amount of delivered nanoparticles in the cells 
must be diluted over 4 weeks of passaging. Perhaps 
the slow degradation of PLL made the delivered anti-
mir-10b molecules still was able to bind to its target 
mir-10b even the amount of anti-10b has been diluted. 
More detailed pharmacokinetics study is needed to 
evaluate the effectiveness and sustainability of this 
nanoparticle delivery system in cells in future.
The  wound-healing  assay  is  widely  used  to 
present useful information for cell proliferations and 
cell  migrations.6,17,18  Although  the  MDA-MB-231 
is  a  model  breast  cancer  cell  line  for  metastasis 
studies,  the  PLL-microRNA-10b  may  also  work 
with  other  type  of  metastasis  breast  cancer  cells. 
And  the  wound-healing  assay  is  the  simplest  test 
for  cell  proliferation  and  migrations,  the  inhibition 
of  wound  healing  may  not  completely  reflect  the 
  cancer metastasis. Boyden-chamber type cell migration 
assay and 3-D culture tests may offer opportunities to 
systematically  study  the  micro-RNA-10b  mediated 
breast  cancer    metastasis. And  this  PLL-microRNA 
nanoparticles may thus offer bright applications for 
prevent the breast cancer metastasis.
In  conclusion,  in  this  study,  we  showed  that  a 
single addition of a trace amount of polylysine-anti-
mir-10b nanoparticle complex into breast cancer cells 
resulted in sustained inhibit the wound-healing for up 
to 4 weeks in breast cancer cells, and the HOXD10 
target RhoC is downregulated. No detectable toxicity 
was associated with the delivery of nanoparticles at 
the tested concentrations. These findings may stimu-
late more studies on the development of targets and 
drugs  that  can  be  further  tailored  toward  specific 
abnormalities in breast cancer.
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Table s1. Thermo stability of anti-mir-10bs.
name Anti-mir-10b (major) Anti-mir-10b (minor)
Sequence 5′-CACAAAUUCggUUCUACAgggUA-3′ 5′-ACAgAUUCgAUUCUAggggAAU-3
Δg 0.6 kcal ⋅ mole−1 −3.68 kcal ⋅ mole−1
TM 14.1 °C 56.9 °C
Δh −15.8 kcal ⋅ mole−1 −38.3 kcal ⋅ mole−1
ΔS −55 cal ⋅ K−1 mole−1 −116 cal ⋅ K−1 mole−1
note: The results are based on the free online software OligoAnalyzer 3.1 from iDTDnA (http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/).
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Figure s1. nanoparticle size was estimated by the dynamic light scattering.
note: The PLL-anti-mir-10b nanoparticle solution was analyzed by DLS. The main peak with an average size of 260nm contained 94% of the nanoparticles
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Figure s2. Cytotoxicity of PLL-anti-mir-10b.
note: MTT cell proliferation method was used to estimate the cytotoxicity of different concentration of anti-mir-10b.
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